Evaluating the Role of Aflapin and Mobilee in Improving Joint Mobility and Reducing Inflammation

Aim: This study aimed to evaluate real-world physician insights regarding the efficacy, safety, and clinical utility of the Aflapin-Mobilee combination in improving joint mobility and reducing inflammation.

Methods: A nationwide, cross-sectional, digital questionnaire-based survey was conducted among physicians in India who routinely prescribe the Aflapin-Mobilee combination. The 35-item questionnaire assessed prescribing patterns, perceived efficacy, safety, onset of symptom improvement, patient response, and considerations for long-term use. Data were analyzed descriptively, with categorical variables summarized as frequencies and percentages.

Results: A total of 83 physicians participated in the study. Most physicians managed patients with established joint disorders, often with prior NSAID use and concurrent inflammatory conditions. Persistent joint pain despite NSAID therapy (40.96%) was the primary reason for initiating the combination. Early pain relief within 2 weeks in 7-9 patients was reported by 40.96% of physicians, and improved joint mobility after 4 weeks was noted in 68.68% of patients. The combination was generally well tolerated, with few mild adverse effects (gastrointestinal discomfort or dizziness, 10.84% each) and rare discontinuation due to intolerance (19.28%). Aflapin-Mobilee was perceived as more effective than NSAIDs by 40.96% of physicians, and 38.55% observed improvement in over 75% of patients’ joint flexibility. The combination was also considered beneficial for long-term joint health, with 55.42% of physicians strongly recommending its continued use. Challenges in prescribing included patient non-adherence (43.37%) and cost (34.94%).

Conclusion: The Aflapin-Mobilee combination is perceived as a safe, well-tolerated, and effective option for improving joint pain and mobility while reducing NSAID dependence. Its synergistic anti-inflammatory and chondroprotective effects support its use as an adjunct or alternative therapy in OA management.